SynAct Pharma Signs Brazil Dengue Deal With Hipolabor
SynAct signed a co-development and commercialization agreement with Hipolabor for resomelagon in dengue in Brazil. SynAct retains global rights for other indications and territories. RESOVIR-2 Part 1 results are expected in 2026, with topline results expected in Q2 2027.